HJB - Your Trusted Biologics CDMO Partner
HJB, CDMO, biologics, HJB Bio, hjbbio, China CDMO, 杭州奕安济世, Just Bio, Just biotherapeutics, HJB bio, HJB China, Hangzhou HJB
We offer a phase-appropriate, and risk-based drug development platform designed to streamline all IND-enabling projects. This ensures fast to clinic, cost benefit, risk mitigation, and seamless tech transfer. Our comprehensive 11-months DNA to IND program (for FDA IND filing) supports multiple therapeutic modalities, reflecting our commitment to delivering one-stop services that meet our clients’ diverse needs. By partnering with us, you gain access to in-depth expertise and propriety platform technologies that maximizes the potential of your molecules while minimizing development cost.
We provide comprehensive services for late-stage development, tailored for companies advancing biologics toward market approval. By utilizing established cell lines for early-stage clinical development and transitioning from fed-batch process to intensified perfusion integrated with hybrid continuous downstream bioprocess, we minimize scaling-up risks while delivering significant advantages. Our approach reduces commercial COGs, enhances supply chain flexibility, and ensures a more efficient pathway to market readiness for your biologics.
CDMO@hjbbio.com
